1.21 | 8.83%
| Price and Volume | |
|---|---|
| Recent Price | 13.70 |
| 52 Week High | 25.25 |
| 52 Week Low | 13.62 |
| Avg. Daily Vol. (Mil) | 0.17 |
| Beta (3 year) | 1.09 |
| Share Related Items | |
| Mkt Cap (Mil) | 495.40 |
| Shares Out (Mil) | 36.16 |
| Float (Mil) | 25.88 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.00 |
| Current Ratio | 5.60 |
| LT Debt/ Equity | 0.14 |
| Total Debt / Equity | 0.15 |
| Valuation Ratios | |
| Price Earnings | 13.20 |
| Price/Sales | 1.62 |
| Price/Book | 1.21 |
| Price/Cash Flow | 10.50 |
| Per Share Data | |
| Earnings | 1.04 |
| Sales | 8.44 |
| Book Value | 11.33 |
| Cash Flow | 1.30 |
| Business Summary | |
|---|---|
| A biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body's immune system to prevent or treat disease. | |
| General Information | |
| 2273 Research Boulevard
Suite 400 Rockville, MD 20850 |
|
| www.emergentbiosolutions.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 811 | |
| CEO: Fuad El-Hibri | |
| Short Interest | |
| Current Month (Mil) | 1.08 |
| Previous Month (Mil) | 1.05 |
| Short Interest Ratio (Days) | 8.10 |
| Management Effectiveness | |
| Return on Equity | 9.20 |
| Return on Assets | 7.30 |
| Return on Investments | 8.00 |
| Profitability | |
| Gross Margin | 87.20 |
| EBIT Margin | 18.30 |
| Profit Margin | 12.30 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,580.69 | 1,332.42 | 2,870.99 | 17.31 |
Oil *
106.73
|
|
UP
125.86 |
UP
14.60 |
UP
33.46 |
DOWN
0.14 |
10 Yr
1.73%
SPDR Gold
151.02
|
|
+1.01%
|
+1.11%
|
+1.18%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet